XTL Biopharmaceuticals Ltd. American Depositary Shares

Beyond Air Inc. (NASDAQ:XAIR) has agreed to sell 85% of its subsidiary NeuroNOS Ltd. to XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) in exchange for 19.9% equity stake in XTL, $1 million cash, and up to $32.5 million in milestone-based payments. NeuroNOS, which focuses on autism therapeutics and holds FDA Orphan Drug Designations, will become XTL's ...

XTL Biopharmaceuticals announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc., positioning itself as a major player in autism therapeutics. The acquisition includes two Nobel Laureates in Chemistry and autism researcher Prof. Haitham Amal. NeuroNOS has secured FDA Orphan Drug Designations for Phelan-McDerm...

XTL Biopharmaceuticals, an Israeli pharmaceutical company, announced the results of its Annual and Extraordinary General Meeting, including the re-election of board members and the appointment of independent auditors. The company also confirmed the acquisition of The Social Proxy Ltd., which will add two new directors to its board.

expands its IP portfolio to AI Web Data

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. AbbVie Inc. (NYSE: ABBV) and Landos Biopharma, reported a definitive agreement under which AbbVie will acquire Landos. Landos Biopharma shares jumped 171.2% to $21.70 on Monday. Here are some other stocks moving in today's mid-day s...